The 2024 Rising Tide/LUNGevity Team Award to Target Mechanisms of Resistance supports high-impact interventional clinical trials that seek to develop therapeutic strategies targeting shared mechanisms of resistance in oncogene-driven lung adenocarcinoma (LUAD). Projects funded are expected to further our knowledge of shared mechanisms of resistance across oncogene-driven LUAD and how they can be targeted using novel pharmaceutical agents (monotherapies or combination therapies).
Applicants must hold a doctoral degree and faculty appointment (or equivalent) with an academic institution, including research institutions that are not formally associated with a university, and have completed a postdoctoral training fellowship. Applicants may be based anywhere in the world. This is a team award and at least two institutions are required to be involved right from the LOI stage
The award provides up to 1,500,000 USD over 3 years (up to 10% indirect costs).
Letters of intent are due on February 9, 2024 and full invited applications are due on May 8, 2024.
May 8, 2024